doi: 10.1056/NEJMp2400978 Summary Keywords GIP, GLP-1, GLP-1RA, tirzepatide, diabetes, obesity, cardiovascular disease Citation Liu QK (2024) Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
In clinical trials, retatrutide has been studied as a once-weekly injection using gradual dose escalation
Pearson correlation analyses between change from baseline in body weight and changes from baseline in Appetite VAS and Eating Inventory at Week 36 were conducted using data for patients included in the efficacy analysis set with a nonmissing baseline value of the response variable
The side effects are predominantly temporary, manageable with the right strategies, and do not outweigh the substantial benefits semaglutide offers for weight management and metabolic health
While taste alterations during treatment with GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists often improve over time as patients adjust to treatment, several strategies can help manage these changes and maintain adequate nutrition and quality of life
